Dr. Vogelzang Discusses Cabozantinib Trial Design

Video

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses cabozantinib trial design.

Dr. Vogelzang says the cabozantinib trial was a nine arm trial. Some of the arms included breast, ovarian, prostate, hepatocellular, lung, gastrointestinal and small cell lung cancer. The trial included nine different categories of patients. All patients received twelve weeks of treatment, after which they underwent scans and appropriate blood tests. If at twelve weeks they were benefiting (as measured by a variety of factors), they were allowed to stay on the drug. If they were felt to be stable, they were randomized to either continue the drug or discontinue the drug. If their X-rays at any time had shown that the cancer was growing, the patient would come off study.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD